Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Gross Profit: 2021-2024

Historic Gross Profit for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $89.1 million.

  • ARS Pharmaceuticals' Gross Profit rose 1471.62% to $32.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.8 million, marking a year-over-year increase of 5395.46%. This contributed to the annual value of $89.1 million for FY2024, which is 297063.33% up from last year.
  • As of FY2024, ARS Pharmaceuticals' Gross Profit stood at $89.1 million, which was up 297,063.33% from $30,000 recorded in FY2023.
  • ARS Pharmaceuticals' 5-year Gross Profit high stood at $89.1 million for FY2024, and its period low was $30,000 during FY2023.
  • For the 3-year period, ARS Pharmaceuticals' Gross Profit averaged around $30.2 million, with its median value being $1.3 million (2022).
  • As far as peak fluctuations go, ARS Pharmaceuticals' Gross Profit tumbled by 97.72% in 2023, and later soared by 297,063.33% in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' Gross Profit (Yearly) stood at $5.5 million in 2021, then slumped by 76.10% to $1.3 million in 2022, then plummeted by 97.72% to $30,000 in 2023, then surged by 297,063.33% to $89.1 million in 2024.